Novel P.UF1 Products Ready for Commercialization

The diversity of the gut microbiota is directly related to human well-being. However, many commercial multi-strain probiotics lack microbial diversity because more than 80% are made up of “lactobacilli” and “bifidobacteria”. SCHISM Bioworks, a Florida-based biotech startup, commercialized “Propionibacterium freudenreichii” P.UF1, which offers a truly unique set of benefits.

Several well-documented preclinical studies have shown that P.UF1 can regulate immune T cells against Listeria monocytogenes infection and colon damage. It also promotes the growth of beneficial bacteria with bifidogenic properties and produces more vitamin B12 (the energy vitamin), as well as significant amounts of B2, B5, C, K, Biotin, Folic Acid, and short-chain fatty acids and amino acids. GUNDRY MD recently announced the release of GI Advantage, the first commercial product made with P.UF1, which aids in the recreation of one’s gut profile when they are younger.

The potential benefits of P.UF1 are still being investigated, but preliminary findings are promising. This strain of bacteria has the potential to provide a variety of health benefits, and it will be exciting to learn about further advances in the field of probiotics.

Probiotics and prebiotics are often seen as two sides of the same coin, and as the choice for probiotics is changing it will be interesting to see if it will also impact the choice of prebiotics.

Company Link


Your email address will not be published. Required fields are marked *



Recent Events


Warning: Undefined variable $temp_year in /home/chembizr/public_html/wp-content/themes/buildo/functions.php on line 426